Myeloma Paper of the Day, October 14th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Left atrioventricular coupling index derived from cardiovascular magnetic resonance imaging may be an independent predictor of all-cause mortality in AL amyloidosis and can further risk stratify Mayo stage IIIa and IIIb patients.”

Cardiovascular magnetic resonance-derived left atrioventricular coupling index as a novel prognostic marker for light-chain amyloidosis

Authors: Yinqiu Wang, Keying Bi, Ke Wan, Jing Liu, Wenzhang He, Xue Li, Linyan Huang, Liqing Peng, Yucheng Chen.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.